



Thursday, 1 October 2026

ICMRA announces its Executive Committee for the 2026-2029 term

As Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA), I am pleased to announce the Executive Committee for the 2026-2029 term. Joining Vice-Chairs Leandro Safatle of the Brazilian Health Regulatory Authority (ANVISA) and Pamela Aung-Thin of Health Canada will be representatives from:

- European Medicines Agency (EMA) with the European Commission's Directorate-General for Health and Food Safety (DG SANTE), European Union
- Ministry of Health, Labour and Welfare (MHLW) with the Pharmaceuticals and Medical Devices Agency (PMDA), Japan
- Health Products Regulatory Authority (HPRA), Ireland
- Health Sciences Authority (HSA), Singapore
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
- Ministry of Food and Drug Safety (MFDS), Republic of Korea
- Swissmedic, Switzerland, and
- US Food and Drug Administration (FDA), United States of America.

This term marks an expansion to the Executive Committee, reflecting ICMRA's growing membership and commitment to broad global representation. Members bring extensive regulatory expertise and leadership that will support ICMRA to navigate emerging challenges, strengthen international regulatory cooperation, and advance public health.

I extend my sincere congratulations to the newly elected and returning members, and thank you for taking on these important roles. I look forward to working closely with the Executive Committee as we build on ICMRA's achievements and advance our shared vision for a more connected, responsive and effective global regulatory community

Professor Anthony Lawler
Chair, International Coalition of Medicines Regulatory Authorities
Deputy Secretary, Therapeutic Goods Administration,
Australian Department of Health, Disability and Ageing